共病作为银屑病患者生物治疗药物生存期的预测因素。
Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis.
作者信息
Jacobi Arnd, Rustenbach Stephan J, Augustin Matthias
机构信息
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany.
出版信息
Int J Dermatol. 2016 Mar;55(3):296-302. doi: 10.1111/ijd.12879. Epub 2015 Oct 15.
BACKGROUND
Psoriasis often requires lifelong therapy, and adherence to treatment is considered a marker for treatment success. Data on the drug survival of biologics in psoriasis patients with comorbidities are lacking.
OBJECTIVES
This study was designed to estimate the long-term drug survival rates of different biologic agents in a cohort of psoriasis patients and to evaluate reasons and predictors for treatment adherence.
METHODS
Drug survival rates and outcome parameters in psoriasis patients treated with biologic agents were analyzed.
RESULTS
A total of 125 treatment periods with adalimumab (n = 37), efalizumab (n = 9), etanercept (n = 55), infliximab (n = 13), and ustekinumab (n = 11) were administered to 67 psoriasis patients. Patients with psoriatic arthritis (P = 0.010) and without comorbidity (P = 0.033) demonstrated significantly greater rates of drug survival.
CONCLUSIONS
The overall efficacy of biologic agents is reduced with time. Patients with the comorbidity of metabolic syndrome demonstrate a loss of adherence to biologic treatment.
背景
银屑病通常需要终身治疗，而坚持治疗被视为治疗成功的一个标志。目前缺乏关于合并症银屑病患者使用生物制剂的药物留存率的数据。
目的
本研究旨在估计一组银屑病患者中不同生物制剂的长期药物留存率，并评估治疗依从性的原因和预测因素。
方法
分析了使用生物制剂治疗的银屑病患者的药物留存率和结局参数。
结果
共对67例银屑病患者进行了125个治疗周期，其中使用阿达木单抗（n = 37）、依法利珠单抗（n = 9）、依那西普（n = 55）、英夫利昔单抗（n = 13）和优特克单抗（n = 11）。银屑病关节炎患者（P = 0.010）和无合并症患者（P = 0.033）的药物留存率显著更高。
结论
生物制剂的总体疗效会随时间降低。合并代谢综合征的患者对生物治疗的依从性会降低。
Zotero 插件